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Abstract
Purpose Tumor hypoxia reduces the efficacy of radiation
and chemotherapy as well as altering gene expression that
promotes cell survival and metastasis. The growth factor
receptor, Her2/neu, is overexpressed in 25–30% of breast
tumors. Tumors that are Her2+ may have an altered state of
oxygenation, relative to Her2- tumors, due to differences
in tumor growth rate and angiogenesis.
Methods Her2 blockade was accomplished using an
antibody to the receptor (trastuzumab; Herceptin). This
study examined the effects of Her2 blockade on tumor
angiogenesis, vascular architecture, and hypoxia in Her2+
and Her2- MCF7 xenograft tumors.
Results Treatment with trastuzumab in Her2+ tumors
significantly improved tumor oxygenation, increased
microvessel density, and improved vascular architecture
compared with the control-treated Her2+ tumors. The
Her2+ xenografts treated with trastuzumab also demon-
strated decreased proliferation indices when compared with
control-treated xenografts. These results indicate that Her2
blockade can improve tumor oxygenation by decreasing
oxygen consumption (reducing tumor cell proliferation and
inducing necrosis) and increasing oxygen delivery (vas-
cular density and architecture).
Conclusions These results support the use of trastuzumab
as an adjunct in the treatment of breast tumors with che-
motherapy or radiotherapy, as improvements in tumor
oxygenation should translate into improved treatment
response.
Keywords Her2/neu  Angiogenesis  Tumor hypoxia 
Breast cancer
Introduction
It is well established that tumor hypoxia is associated with
treatment resistance, aggressive clinical phenotype, and
poor prognosis [1, 2]. There are multiple reasons for the
negative effect of hypoxia on treatment response, including
direct interference with the treatment efficacy of radiation
and drugs, and altered gene expression that promotes
angiogenesis, cell survival, and metastasis [3–8]. Hypoxia-
responsive genes are involved in many cell functions: cell
cycle control, apoptosis regulation, angiogenesis, regula-
tion of metabolism, and protection of cells from oxidative
stress. The role of hypoxia in tumor multi-drug resistance,
invasiveness, angiogenesis, and metastasis is currently an
area of intense research interest.
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The factors that contribute most to limiting oxygen
transport are low vascular density coupled with irregular
geometry and oxygen consumption that is out of balance
with supply [9, 10]. Oxygen consumption rates in prolif-
erating cells are 3–5 times greater than cells in Go [11, 12],
and variations in oxygen consumption rate of this order
of magnitude would be expected to completely dominate
oxygen transport, producing hypoxic tissue [9]. Low vas-
cular density and increased O2 consumption are affected by
Her2/neu expression in tumors. Laboratory studies have
shown that Her2 overexpression increases breast tumor cell
proliferation which should increase oxygen consumption
rates [13–16]. However, Her2 overexpression can also
drive angiogenesis by increasing expression of the pro-
angiogenic cytokine vascular endothelial growth factor
(VEGF), independent of hypoxic upregulation [17]. Petit
et al. reported the first observation of a relationship
between Her2 overexpression and VEGF. In this report, the
use of trastuzumab in Her2 positive cell lines reduced
VEGF expression. Other studies have demonstrated that
Her2 and EGFR overexpression can lead to increased
levels of HIF-1 and VEGF [18, 19].
Because inhibition of Her2 signaling can inhibit both
cell proliferation and angiogenesis, predictions about
changes in tumor oxygenation following inhibition of Her2
signaling are difficult to make. In an attempt to determine
the change in the net balance between oxygen delivery and
consumption, this study examines the effect of Her2
blockade on intratumoral pO2, microvessel density, tumor
vascular architecture, necrosis and tumor cell proliferation
in a model of Her2+ and Her2- human breast tumor
xenografts. The reasons for an increase in tumor oxygen-
ation following trastuzumab treatment are multifactorial.
Improvements in vascular density and organization as well
as reduction in oxygen consumption rate all contribute to
the overall increase in tumor pO2.
Materials and methods
Tumor model
Two MCF7 human breast cancer cell lines were used in all
experiments: parent MCF7WT cell line (Her2 non-
expressing) and MCF7Her2, which is a stable cell line that
has been transfected to constitutively overexpress Her2
(Fig. 1).
The MCF7Her2 line was created by transfection of
pcDNA3.1 containing the full-length wild type coding
sequence of human ERBB2. In parallel, cells were also
transfected with the empty vector. After 2 days, cells were
selected in RPMI containing 10% FBS and 600 lg/ml
G418 (Mediatech, Herndon, VA) until colonies of
approximately 200 cells developed. Single colonies from
both the ERBB2 and empty vector were isolated by cloning
cylinders, transferred to 24 well dishes and grown in
medium containing G418. These clones were then assayed
for ERBB2 expression by immunoblotting and comparison
to the parental line and empty vector clones. After selec-
tion, cells are maintained in medium containing 100 lg/ml
G418. The clone selected for these studies expresses
ERBB2 protein at approximately 100-fold over the parental
and empty vector control cells. Further, by FISH analysis,
it was determined that these cells contain 13–14 copies of
the ERBB2 coding sequence.
All animal experiments were performed in accordance
with Duke University’s institutional animal care and use
committee. After estrogen pellet implantation (Innovative
Research of America, Sarasota, FL), female nude mice
(BALB/c nu/nu), weighing approximately 20 g were
injected with 107 tumor cells subcutaneously into the left
flank. Tumors volumes were measured until they reached
100 mm3. Animals were then randomized to Her2 block-
ade (trastuzumab 10 mg/kg IP daily) or control (Human
Myeloma IgG1 10 mg/kg IP daily; Biodesign, Saco, ME).
Treatment was continued for 2 weeks. Tumor dimensions
were measured thrice per week, and volume was calculated
by the following formula:
Volume ¼ length  width  height  p=6
Intratumoral pO2 measurements
Following the 2-week treatment with trastuzumab or pla-
cebo, animals were anesthetized with nembutal 75 mg/kg
and placed on a heating pad. Oxygen measurements were
Fig. 1 Transfected MCF7-Her2 cells overexpress Her2. Shown is an
immunoblot of MCF7WT and transfected MCF7Her2 tumor cells for
p185/Her2, along with actin loading control
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performed using a fiber optic oxygen-sensing device
(Oxford Optronix, Oxylite). Two profiles were obtained
with a micromanipulator, using a 50 lm step distance
(200–300 measurements per tumor). Following pO2 mea-
surements, the animals were euthanized with an overdose
of nembutal.
Tumor excision
Additional animals were administered pimonidazole
hydrochloride (Natural Pharmaceuticals, International Inc.,
Belmont, MA) 70 mg/kg intraperitoneally, for immuno-
histochemical determination of hypoxia. After 3–4 h, the
mice were anesthetized with nembutal at 10 mg/kg and
placed on a heating pad for tumor excision. After tumor
excision, specimens were immediately snap-frozen. Com-
plete tumor sections from 4 or 5 animals in each group
(8–10 lm thickness) were cut and stored at -80C until
further processing. Each of the tumors was stained and
analyzed for hypoxia (pimonidazole), endothelial struc-
tures (CD31), proliferation (Ki67), and VEGF expression.
Tumor sections were also stained with hematoxylin and
eosin (H&E) to distinguish viable from necrotic tissue.
Immunohistochemistry
Immunohistochemistry was performed using protocols
designed for single images or whole tumor sections.
For single image analysis, endogenous peroxidase
activity was quenched with 3% hydrogen peroxide for
15 min, followed by blocking with 10% donkey serum for
15 min. The slides were then incubated with primary anti-
bodies: anti-rabbit VEGF antibody (Santa Cruz, dilution
1:400) overnight at 4C; anti-Ki67 rabbit monoclonal
antibody (Vector Lab; dilution 1:4,000) overnight at 4C;
and mouse monoclonal anti-pimonidazole (hypoxyprobe-1
(Chemicon; Temecula, CA); dilution 1:100). Washing was
accomplished with phosphate-buffered saline (PBS).
Omission of the primary antibody served as negative con-
trol. Secondary antibodies were applied for 1 h as follows:
biotinylated donkey anti-rabbit antibody (VEGF, Ki67);
Cy-3-conjugated donkey anti-mouse antibody (pimonidaz-
ole; 1:200 for 2 h; Chemicon). Visualization of Ki67 and
VEGF staining was accomplished with ABC kit (Vector
Lab, Inc., Burlingame, USA). Slides were again washed in
PBS and color was developed by 5 min incubation in dia-
minobezidine (DAB) solution. Slides were counterstained
with H&E. For Ki67 staining, Novared kit (Vector Lab Inc.,
Burlingame, USA) was used to develop red color for 5 min.
For whole tumor analysis, the slides were fixed in ace-
tone for 20 min, then blocked with the primary antibody
dilution buffer for 30 min. The slides were incubated with
the primary antibody for 1 h: rat anti-mouse CD31 (BD,
dilution 1:200). After washing with PBS, the slides were
incubated with Cy2-conjugated donkey anti-rat (Jackson
Immunoresearch, 1:100) for 30 min, washed with PBS and
fixed in 4% PFA for 15 min. The slides were immediately
imaged.
Image collection and analysis
The tumor sections were quantitatively analyzed with a
method based on a computerized digital image-analysis
system. A high-resolution, intensified solid-state camera on
a fluorescence microscope (Axioskop [Zeiss, Germany])
was used. The images were recorded, processed, and ana-
lyzed using the digital imaging application Axiovision. For
quantitation purposes, Adobe Photoshop and MATLAB
(MathWorks, Inc., Natick, MA) were used. Histologic
analysis was not performed on areas of oxygen probe
measurement to avoid areas that might have been damaged
by probe placement.
VEGF. After the slides were scanned at low magnifi-
cation (409), three areas (per animal) of maximum VEGF
expression were selected (4009). The degree of positive
VEGF staining on the section was assessed at low mag-
nification (409). The percentage of tumor cells staining for
VEGF was analyzed by measuring positively stained pix-
els/total pixels. The mean value of the examined fields was
calculated (and grouped together to represent each animal).
Ki67. After the slides were scanned at low magnification
(409), the cells with positively stained nuclei were counted
in three fields at a magnification of 4009. Total number of
tumor cells was counted in each field and Ki67 index was
calculated as the percentage of positive cells/total cells.
Hypoxia evaluation. The slides were scanned at low
magnification (409) using a TRITC filter to identify three
hypoxic areas that were captured. The hypoxic fraction was
calculated as the area of hypoxic staining divided by the
total area. Necrotic areas within each section were exclu-
ded on the basis of H&E staining.
Whole tumor analysis. The slides were imaged using a
computer controlled scanning stage and later ‘‘stitched’’
together to gain one image of the entire tumor. Fluores-
cence images were acquired with a monochromatic CCD
camera and 109 objective (pixel size = 1.48 by 1.48 lm).
Color images were acquired with a color CCD camera and
a 59 objective (pixel size = 0.69 by 0.69 lm). These
images for each tumor were aligned in Adobe Photoshop
and a series of masks were created: tumor mask, necrotic
mask, and necrotic edge mask. These masks and the ori-
ginal fluorescence image of tumor blood vessels (CD31+),
isolated with a thresholding procedure [20], were analyzed
with custom Matlab software to calculate the necrotic
fraction, MVD, median distance to the vascular surface
(MDVS) from viable tumor and the median distance to the
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necrotic edge (MDNE) from the vascular surface. The
MDVS describes the vascular spatial frequency and
architecture, where a shorter distance indicates a better
organized vascular network for oxygen delivery. MDNE
represents a ratio of supply to demand convolved with the
inherent cell disposition to die. These data are presented as
the median distance ± SEM.
The distance from each pixel to the nearest blood vessel
was calculated in Matlab and displayed as a cumulative
frequency of distances. This distance represents the mini-
mum distance that a solute (e.g., oxygen) must travel from
the blood vessel to a tumor cell such that larger values
suggest that a solute has a larger distance to travel in order
to reach that tumor cell. For a constant amount of tumor
cell consumption and vascular concentration, larger dis-
tances indicated a vascular network that is not as efficient
for transport as a vascular network with shorter distances.
For all immunohistochemical endpoints, the observers
were blinded to the treatment groups during data acquisition.
Statistics
Statistical analyses were done similarly for all endpoints.
Tumor growth and oxygenation data were compared using
Student’s t test. Endpoints for each tumor line, MVD, pi-
monidazole, VEGF, and Ki67 immunohistochemistry were
evaluated with a global ANOVA with treatment group as
the factor and a Fisher’s PLSD post hoc test (Statview,
SAS Institute, Cary, NC). Values are expressed as
mean ± SEM. P values of \0.05 were considered statis-
tically significant. All statistical tests were two sided.
Results
Her2 blockade increases tumor oxygenation
Treatment with trastuzumab over 2 weeks, as predicted,
statistically significantly reduced tumor size in MCF7Her2
tumors (mean volume of control MCF7Her2 tumors was
235.3 mm3 vs 62.5 mm3 for trastuzumab-treated tumors;
P \ 0.05; t test). There was no statistically significant
effect of Her2 blockade on MCF7WT tumor growth, but
there was a trend toward smaller tumors in the trast-
uzumab-treated group (Table 1). This may be explained by
the trend in proliferation index (below).
Tumor oxygenation status was determined by direct
pO2 measurements. When measured directly, trastuzumab-
treated animals with MCF7Her2 tumors (N = 5) had a mean
pO2 of 16 mmHg ± 0.79, whereas control-treated animals
with MCF7Her2 tumors (N = 5) had a lower pO2 of
12 mmHg ± 0.75 (Table 1). MCF7Her2 tumors treated with
trastuzumab also had a lower fraction of pO2 measurements
less than 10% (41% in the trastuzumab-treated group vs
62% in the control-treated group). The difference was sta-
tistically significant (P \ 0.05; t test) indicating that Her2
blockade in MCF7Her2 tumors improved tumor oxygena-
tion. Mean pO2 values were not significantly different
between MCF7WT tumors treated with trastuzumab (N = 5)
or control (N = 5), 21 mmHg ± 5.9 and 23 mmHg ± 3.2,
respectively (P [ 0.05; t test). MCF7Her2 tumors were sta-
tistically significantly more hypoxic (12 mmHg) than the
MCF7WT tumors (23 mmHg), suggesting that Her2 over-
expression results in increased tumor hypoxia (P \ 0.05; t
test). Her2 overexpression also resulted in a higher fraction
of pO2 measurements below 10% (62% in the MCF7
Her2
control-treated tumors vs 26% in the MCF7WT control-
treated tumors, Table 1).
Determinations of hypoxia were also done using pi-
monidazole staining of tumor sections. Quantitation of
immunohistochemical staining of tumor sections revealed
patterns similar to the above direct oxygenation measure-
ments. Control MCF7WT tumors had a mean hypoxic
fraction of 0.22, while that of trastuzumab-treated
MCF7WT tumors was 0.29 (P = 0.04; ANOVA). In con-
trast, control MCF7Her2 tumors had a mean hypoxic
fraction of 0.64, while trastuzumab treatment significantly
Table 1 Tumor pO2
MCF7WT control MCF7WT trastuzumab MCF7Her2 control MCF7Her2 trastuzumab
Mean pO2 (mmHg) 23 ± 3.2 21 ± 5.9 12 ± 0.75* 16 ± 0.79**
% pO2 \ 10 mmHg 29 ± 7.6 26 ± 3.9 62 ± 2.5*** 41 ± 4.6

Mean endpoint tumor volume (mm3) 313 ± 59 249 ± 33 235 ± 29 62 ± 15
n 5 5 5 5
* MCF7WT vs MCF7Her2 control-treated; P \ 0.05; t test
** MCF7Her2 control-treated vs MCF7Her2 trastuzumab-treated; P \ 0.05; t test
*** MCF7Her2 control-treated vs MCF7WT control-treated; P \ 0.05; t test
 MCF7Her2 control-treated vs MCF7Her2 trastuzumab-treated; P \ 0.05; t test
 MCF7Her2 control-treated vs MCF7Her2 trastuszumab-treated; P \ 0.05; t test
pO2 measurements were done immediately after the 2 week treatment using an Oxylite fiber-optic oxygen probe. The mean pO2 values are given
in mmHg ± standard deviation
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reduced the hypoxic fraction to 0.46 (P = 0.016;
ANOVA). MCF7Her2 control-treated tumors were statisti-
cally significantly more hypoxic than MCF7WT control-
treated tumors (Table 2, Fig. 2a, d; P = 0.001; ANOVA).
Her2 blockade inhibits tumor cell proliferation
Her2 overexpression in this MCF7 tumor cell line
increased proliferation index. Based on Ki67 staining,
control-treated MCF7WT cells had a mean proliferation
index in vivo of 51 ± 2%, while MCF7Her2 control-treated
cells had a mean proliferation index of 70 ± 3% (Table 2,
Fig. 2d; P = 0.001; ANOVA).
Her2 blockade was effective in reducing the proliferation
index. MCF7Her2 tumors treated with trastuzumab had a
mean proliferation index of 47 ± 3%, whereas in control
tumors, the mean proliferation index was 60 ± 3%
(Table 2, Fig. 2b, d). This represents a significant decrease
in proliferative cells in the trastuzumab-treated MCF7Her2
tumors when compared with controls (P = 0.03; ANOVA).
Trastuzumab- and control-treated MCF7WT tumors did not
have significantly different proliferative indices, 44 ± 3
and 51 ± 2%, respectively (P = 0.10; ANOVA), although
there is a clear trend that corresponds to a trend in smaller
tumors in the trastuzumab-treated group.
Her2 blockade improves tumor vascular architecture
Mean percent area positive for VEGF was lower in
MCF7Her2 tumors treated with trastuzumab vs controls
(35 ± 11 and 76 ± 1%, respectively; Table 2, Fig. 2c).
These values represent a statistically significant reduction
in VEGF expression (P = 0.02; t test). Mean VEGF
staining was not different in trastuzumab-treated and
control MCF7WT tumors: 25 ± 4 and 25 ± 2%, respec-
tively (P = 0.41; t test).
An evaluation of the vascular architecture was accom-
plished using whole tumor images (Fig. 3a, b). In addition,
vascular density was determined from high magnification
images (4009) of CD31-stained tumor sections. Her2
signaling blockade in MCF7Her2 tumors resulted in sig-
nificantly increased vascular density from 84 ± 12 vessels
per mm2 in control tumors to 150 ± 28 in trastuzumab-
treated tumors (Table 3, Fig. 4a; P = 0.01; Fisher’s
PLSD). Vascular density was not significantly different
between control MCF7WT and MCF7Her2 tumors, as well as
between control- and trastuzumab-treated MCF7WT tumors
(P [ 0.05, Fisher’s PLSD).
The median distance to vascular surface (MDVS) was
relatively similar for both trastuzumab-treated and control
MCF7WT tumors, as well as for both control MCF7WT
and MCF7Her2 tumors (Table 3, Fig. 4b). However, Her2
blockade in MCF7Her2 tumors reduced the MDVS to
35 ± 4 compared to a MDVS of 47 ± 4 lm in control
MCF7Her2 tumors, resulting in tumors with more evenly
spaced blood vessels and shorter distances between blood
vessels and tumor cells. This relationship is also repre-
sented in a cumulative frequency plot in Fig. 4c. This
difference in vascular architecture indicates that trast-
uzumab treated MCF7Her tumors had a more efficient
vascular architecture for oxygen transport than control
MCF7Her2 tumors.
Her2 blockade in MCF7Her tumors exhibited a trend in the
median distance to necrotic edge (MDNE). The MDNE in
control MCF7Her tumors was 97 ± 11, however, in trast-
uzumab-treated MCF7Her2 tumors this distance was reduced
to 62 ± 11 lm (Table 3, Fig. 4b). MDNE was not statisti-
cally different between control MCF7WT and MCF7Her2 or
trastuzumab-treated MCF7WT tumors. Considering that
Table 2 Immunohistochemical analysis of tumors
MCF7WT control MCF7WT trastuzumab MCF7Her2 control MCF7Her2 trastuzumab
Hypoxic fraction (pimonidazole) 0.22 ± 0.04 0.29 ± 0.06 0.64 ± 0.08* 0.46 ± 0.04**
VEGF expression % area (+) 25 ± 2 25 ± 4 76 ± 1*** 35 ± 11
Proliferation index (Ki67) 51 ± 2 44 ± 3 60 ± 3 47 ± 3
Hypoxic fraction is reported as the percentage of pimonidazole-stained tumor cells over the total number of cells in the tumor sec-
tion 9 100 ± SEM. Relative VEGF expression is reported as the ratio of VEGF stained area over the total tumor parenchymal
area 9 100 ± SEM. Proliferation index is reported as the number of positively staining nuclei over the total number of nuclei in the
field 9 100 ± SEM
* MCF7WT vs MCF7Her2 control-treated; P = 0.001; ANOVA
** MCF7Her2 control-treated vs MCF7Her2 trastuzumab-treated; P = 0.016; ANOVA
*** MCF7WT vs MCF7Her2 control-treated; P = 0.0001; ANOVA
 MCF7Her2 control-treated vs MCF7Her2 trastuzumab-treated; P = 0.02; ANOVA
 MCF7WT control-treated vs MCF7Her2 control-treated; P = 0.001; ANOVA
 MCF7Her2 control-treated vs MCF7Her2 trastuzumab-treated; P = 0.03; ANOVA
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trastuzumab treated MCF7Her2 tumors had a greater MVD
than other tumors, this shorter distance to the necrotic edge
suggests that the trastuzumab treated MCF7Her2 tumors were
more susceptible to death from nutrient depletion, as com-
pared with the other experimental groups.
Discussion
Oxygen consumption rate, vascular density and vascular
architecture are among the main physiologic determinants
of oxygen transport in tumors [10, 21]. In this paper, we
demonstrate that all three features are affected by Her2/neu
overexpression. Several clinical reports indicate that
increased tumor cell proliferation is associated with over-
expression of Her2 [13–16]. Her2 overexpression can also
result in increased blood vessel growth as a result of its
influence on VEGF expression [18, 19]. The balance
between these two functions of Her2 will likely dictate the
oxygenation status of Her2 positive tumors under baseline
conditions and in response to Her2 function blockade.
The results of this study indicate that Her2 overexpres-
sion creates a more hypoxic environment, reflected by both
oxygen probe and pimonidazole immunohistochemistry
measurements. The poorer oxygenation is a result of either
inefficiencies in oxygen transport created by lower vascular
density, more irregular vascular geometry or tumor cell
proliferation [10]. The results of the MDVS are helpful in
this regard. This value was not different between wild type
and Her2 overexpressing tumors. This indicates that the
vascular architecture, as assessed by this method, cannot
explain the higher hypoxic fraction in the Her2 over-
expressing tumors. Therefore, one can conclude that the
main determinant of the greater degree of hypoxia is the
higher growth fraction, i.e., tumor cell proliferation.
Simulations of oxygen transport in tumor models, based
on experimental measurements of vascular architecture and
other relevant parameters have indicated that large changes
in oxygenation can be induced by as little as 30% change in
oxygen consumption rate [9]. This change in oxygen con-
sumption rate is in the order of magnitude seen in this
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vivo was around 50% and this increased to approximately
70% in Her2 overexpressing tumors. Oxygen consumption
rates for proliferating cells are approximately 3–5-fold
higher than that of quiescent cells [12, 22]. This 20%
difference in proliferation could easily induce a large
difference in hypoxia based on previous modeling by Se-
comb et al. [10].
To illustrate this point, we describe a relatively
straightforward way to estimate differences in oxygen
consumption rate, based on differences in the proliferative
fraction. Relative metabolic rates (compared with a tumor
with a proliferative fraction of zero) were estimated for
each experimental group using the following equation:
Relative Metabolic Rate ¼ proliferative fractionð Þ  4
þ non-proliferative fractionð Þ
 1
The multipliers of 4 and 1 come from the average differ-
ence in oxygen consumption rates for proliferative and
quiescent cells, as referenced above (Table 4). Using these
numbers, it is possible to compare oxygen consumption
rates between experimental groups. The ratio of relative
oxygen consumption rates between control MCF7WT and
MCF7Her2 tumors is 2.80/2.53 = 1.11, indicating that the
oxygen consumption rate of the Her2 overexpressing line is
about 10% higher than the wild type line. In the analysis by
Fig. 3 Whole tumor vessel analysis. Shown are whole tumor
representative images from immunohistochemical staining of
MCF7WT (control- and trastuzumab-treated) and MCF7Her2 (control-
and trastuzumab-treated) tumors. In a, whole tumor images of H&E
staining are shown. The distance map is shown in b where a distance
of zero is dark blue (online) and a distance of 200 lm is shown as
dark red (online) (all distances [200 lm are shown as dark red). In
MCF7Her2 tumors, treatment with trastuzumab results in a ‘‘normal-
ization’’ of the vascular architecture, illustrated by a more regular
distribution of vascular distances in b. The necrotic area is indicated
by black regions and non-tumor area is white. The scale bar is 3 mm
Table 3 Summary of vessel analysis
MCF7WT control MCF7WT trastuzumab MCF7Her2 control MCF7Her2 trastuzumab
Total tumor area (mm2) 35.4 ± 12.2 34.1 ± 8.8 21.4 ± 11.6NS 6.5 ± 3.1NS
Necrotic fraction 0.24 ± 0.08 0.18 ± 0.09 0.06 ± 0.03NS 0.07 ± 0.05NS
Vascular density (vessels/mm2) 95 ± 8 82 ± 7 84 ± 12NS 150 ± 28*
Area per vessel (lm2) 258 ± 31 206 ± 30 250 ± 32 246 ± 19
Median distance to vascular surface (MDVS; mm) 47.4 ± 4 50.5 ± 3 47 ± 4 35 ± 4NS
Median distance to necrotic edge (MDNE; mm) 95 ± 11 97 ± 5 97 ± 11 62 ± 11NS
A variety of vessel analyses were performed on MCF7WT and MCF7Her2 tumors treated with control and trastuzumab, including total tumor area
(mm2), necrotic fraction, vascular density (vessels/mm2), area per vessel (lm2), median distance to vascular surface (MDVS; lm) and median
distance to necrotic edge (MDNE; lm)
* MCF7Her2 trastuzumab-treated vs MCF7Her2 control-treated; P = 0.03; ANOVA
NS Not statistically significant; P [ 0.05
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Secomb, a 30% reduction in oxygen consumption rate was
successful in reducing the hypoxic fraction from 12% to
zero. In the current analysis, there is a 40% difference in
hypoxic fraction between the two control groups. Because
the difference in hypoxic fraction is so much greater than
the 12% reduction predicted by Secomb for a 30% drop in
oxygen consumption rate, we suggest that factors other
than oxygen consumption rate are playing a role. It is
possible that the Her2 overexpressing line is more meta-
bolically active because of other factors aside from
proliferation—such as differences in cell motility and
invasion. Alternatively there may be other differences in
the ability of the microvasculature to deliver oxygen effi-
ciently. We are not able to discern from our data, for
example, whether there are differences in shunt flow
between these tumor types, which could very well be the
case in the Her2 overexpressing line, since it has a sig-
nificantly higher level of VEGF expression, which would
tend to lead to higher diameter blood vessels [23].
When trastuzumab was administered to Her2 over-
expressing tumors, there were significant reductions in cell
proliferation, VEGF expression, an increase in vascular
density and a trend toward an improvement in vascular
architecture, reflected by the shortening of MDVS. This
result is consistent with a duality of effects induced by
trastuzumab treatment in the MCF7 Her2 overexpressing
line. The reduction in proliferation likely caused a reduc-
tion in oxygen consumption rate and the increase in
vascular density likely improved oxygen delivery.
The ratio of relative oxygen consumption rates for
MCF7WT tumors was 1.09 (control-treated/trastuzumab-
treated). The proliferation index was not statistically sig-
nificantly different between MCF7WT groups, which is
consistent with there being no significant difference in the
degree of hypoxia between these two groups., In contrast,
the proliferation rate in the MCF7Her2 tumors after treat-
ment with trastuzumab was significantly lower than the
control, yielding a ratio of relative oxygen consumption
rates of 1.16. This difference in oxygen consumption cor-
related with a 20% drop in hypoxic fraction, measured by
both pimonidazole immunohistochemistry and the probe
Fig. 4 Tumor vascular spatial frequency and architecture. Her2
overexpression creates sparser and more unevenly spaced vascular
networks. Treatment of MCF7Her2 tumors with trastuzumab restored
the tumor vasculature spatial frequency and distribution to MCF7WT
tumor’s values, demonstrated by increased vascular density (a),
decreased median distance to vascular surface (MDVS) and median
distance to necrotic edge (MDNE) (b), and a shift in cumulative
frequency to higher distance values (c)
Table 4 Relative metabolic rates





See ‘‘Discussion’’ for details on how these values were calculated
226 Cancer Chemother Pharmacol (2009) 63:219–228
123
measurement method. We cannot rule out that the increase
in microvessel density induced by trastuzumab treatment
may also play a role in influencing the degree of hypoxia,
however.
Additional work is required to completely resolve which
of these additional mechanisms might be in play to explain
the differences in hypoxic fraction. We believe that simple
measurement of oxygen consumption rate would be
insufficient to explain the differences, however, because
factors such as differences in motility and invasion could
not be taken into account using standard methods, which
require measurement of cells in suspension culture in
sealed tubes [24].
Our findings appear to be in contrast to studies showing
no effects of trastuzumab on the fraction of viable hypoxic
Her2 + tumor cells [25]. In this study, Warburton et al.
examined the effects of trastuzumab alone and in combi-
nation with gefitinib, a selective small molecule inhibitor
of EGFR. However, one main difference in our study lies
in our measurements of tumor oxygenation in vivo, as well
as by immunohistochemistry, whereas previous studies
determined hypoxia in single-cell suspensions by flow
cytometry.
An unexpected additional observation was a trend in the
reduction in distance to nearest necrotic edge. These results
suggest that trastuzmab treated Her2 overexpressing cells
may be more sensitive to nutrient withdrawal than the
untreated control and wildtype cells, given that their
oxygenation was improved. This may reflect a lowered
capacity to switch from aerobic to anaerobic metabolism,
resulting in lower threshold for cell death [26]. We have
shown previously that both oxygen and glucose gradients
contribute to nutrient depletion and necrosis [27]. Addi-
tional studies to examine nutrient gradients in these tumor
models might yield mechanistic information underlying the
contribution of nutrient depletion to necrosis.
There have been conflicting reports on the effects of
trastuzumab on tumor vasculature. Dragowska et al.
demonstrated increased VEGF levels and an increased
viable hypoxic cell fraction in tumors subjected to Her2
blockade, but failed to demonstrate a difference in tumor
vascularization [28]. Izumi et al. examined the effects of
Her2 blockade on blood vessel diameter, length, volume
and permeability in Her2(+) mouse breast tumors [29].
They demonstrated a reduction in diameter, vascular
volume, and permeability (but not length) of tumor blood
vessels, which they coined the ‘‘normalization’’ of tumor
blood vessels [30]. Our result is somewhat consistent
with this prior work. In this model system, the pruning
of vasculature following administration of trastuzumab to
Her2 + tumors occurs at a pace that is slower than loss
of tumor cells. This is reflected by a net increase in
vascular density and decrease in MDVS. We clearly
observed a reduction in overall VEGF levels, indicating
that the increase in vascular density is not likely due to
stimulation of angiogenesis. We show here that the
improvement in oxygenation is a more complex function,
involving a combination of cell loss from necrosis,
reduced oxygen consumption and improved vascular
architecture.
Trastuzumab is the first of a cohort of drugs that inter-
fere with Her2 function. The small molecule tyrosine
kinase inhibitor, lapatinib, combined with capecitabine was
recently shown to prolong progression free survival in
patients with Her2 positive locally advanced or metastatic
breast cancer, who had already failed several other che-
motherapy regimens [31]. These drugs will have wide
ranging clinical applications for tumors that overexpress
this receptor. It is important to keep in mind the changes
in microenvironment created by Her2 blockade. The
improvements in transport definitely increase oxygenation,
but will also improve drug delivery as well. One would
expect improved cell killing by radiation and a variety of
traditional chemotherapeutic drugs that are known to be
influenced by inefficiencies in delivery and hypoxia [32].
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
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